Medical Oncology

, 31:785 | Cite as

MicroRNA-205 suppresses proliferation and promotes apoptosis in laryngeal squamous cell carcinoma

  • Linli Tian
  • Jiarui Zhang
  • Jingchun Ge
  • Hui Xiao
  • Jianguang Lu
  • Songbin Fu
  • Ming LiuEmail author
  • Yanan SunEmail author
Original Paper


MicroRNAs were reported to be involved in the modulation of tumor development. The aim of our study was to investigate the effect of miR-205 on proliferation and apoptosis of laryngeal squamous cell carcinoma (LSCC) and seek associations between miR-205 and Bcl-2 using in vitro and in vivo methods. Real-time qPCR was used to analyze the expression of miR-205 in LSCC samples and Hep-2 cell line. Apoptosis, cell cycle, and proliferation (MTT) assays were performed to test the apoptosis and proliferation of LSCC cells after miR-205 transfection. Bcl-2 expression in cells was assessed with Western blotting. The tumorigenicity of LSCC cells was evaluated in nude mice model. MiR-205 was significantly down-regulated in LSCC tissues compared to adjacent normal tissues. Lower expression of miR-205 was indicated to be statistically related with advanced clinical stage and T3–4 grades. We found that restoration of miR-205 down-regulated the proliferative markers of dihydrofolate reductase and proliferating cell nuclear antigen and apoptotic regulator of Bcl-2. The findings in vitro and in vivo showed miR-205 could suppress cell proliferation and induce cell apoptosis. In addition, Bcl-2 was identified as one of the direct targets of miR-205 in LSCC cells. These results suggest that miR-205 may play as a tumor suppressor in LSCC, probably by targeting Bcl-2 and serve as a potential target for therapeutic intervention.


Laryngeal squamous cell carcinoma MiR-205 Bcl-2 Proliferation Apoptosis 



The research was supported by grants from the Heilongjiang Postdoctoral Fund (LBH-Z12157), the foundation of Heilongjiang Educational Committee (12531343), the foundation of Heilongjiang Health Bureau (2012-624), the Youth Foundation of the Second Affiliated Hospital of Harbin Medical University (QN2011-01), the National science Foundation of china (81241085, 81372902, 81272965), the key project of Natural Science Foundation of Heilongjiang Province of China (ZD201215/H1302), the Research Fund for the Doctoral Program of Higher Education of China (20102307110007), and the science and technology innovation talent research funds of Harbin (2012RFXXS072).

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Chu EA, Kim YJ. Laryngeal cancer: diagnosis and preoperative work-up. Otolaryngol Clin North Am. 2008;41:673–95.PubMedCrossRefGoogle Scholar
  2. 2.
    Jiang J, Lee EJ, Gusev Y, Schmittgen TD. Real-time expression profiling of microRNA precursors in human cancer cell lines. Nucleic Acids Res. 2005;33:5394–403.PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Tran N, McLean T, Zhang X, Zhao CJ, Thomson JM, O’Brien C, et al. MicroRNA expression profiles in head and neck cancer cell lines. Biochem Biophys Res Commun. 2007;358:12–7.PubMedCrossRefGoogle Scholar
  4. 4.
    Childs G, Fazzari M, Kung G, Kawachi N, Brandwein-Gensler M, McLemore M, et al. Low-level expression of microRNAs let-7d and miR-205 are prognostic markers of head and neck squamous cell carcinoma. Am J Pathol. 2009;174:736–45.PubMedCrossRefGoogle Scholar
  5. 5.
    Ren J, Zhu D, Liu M, Sun Y, Tian L. Downregulation of miR-21 modulates Ras expression to promote apoptosis and suppress invasion of laryngeal squamous cell carcinoma. Eur J Cancer. 2010;46:3409–16.PubMedCrossRefGoogle Scholar
  6. 6.
    Zhang T, Liu M, Wang C, Lin C, Sun Y, Jin D. Down-regulation of MiR-206 promotes proliferation and invasion of laryngeal cancer by regulating VEGF expression. Anticancer Res. 2011;31:3859–63.PubMedGoogle Scholar
  7. 7.
    Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–97.PubMedCrossRefGoogle Scholar
  8. 8.
    Ambros V. MicroRNA pathways in flies and worms: growth, death, fat, stress, and timing. Cell. 2003;113:673–6.PubMedCrossRefGoogle Scholar
  9. 9.
    Fabian MR, Sonenberg N, Filipowicz W. Regulation of mRNA translation and stability by microRNAs. Annu Rev Biochem. 2010;79:351–79.PubMedCrossRefGoogle Scholar
  10. 10.
    Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005;120:15–20.PubMedCrossRefGoogle Scholar
  11. 11.
    Esquela-Kerscher A, Slack FJ. Oncomirs—microRNAs with a role in cancer. Nat Rev Cancer. 2006;6:259–69.PubMedCrossRefGoogle Scholar
  12. 12.
    Garzon R, Calin GA, Croce CM. MicroRNAs in cancer. Annu Rev Med. 2009;60:167–79.PubMedCrossRefGoogle Scholar
  13. 13.
    Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6:857–66.PubMedCrossRefGoogle Scholar
  14. 14.
    Krutzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M, et al. Silencing of microRNAs in vivo with ‘antagomirs’. Nature. 2005;438:685–9.PubMedCrossRefGoogle Scholar
  15. 15.
    Elmén J, Lindow M, Schütz S, Lawrence M, Petri A, Obad S, et al. LNA-mediated microRNA silencing in non-human primates. Nature. 2008;452:896–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Wu H, Zhu S, Mo YY. Suppression of cell growth and invasion by miR-205 in breast cancer. Cell Res. 2009;19:439–48.PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Wiklund ED, Bramsen JB, Hulf T, Dyrskjøt L, Ramanathan R, Hansen TB, et al. Coordinated epigenetic repression of the miR-200 family and miR-205 in invasive bladder cancer. Int J Cancer. 2011;128:1327–34.PubMedCrossRefGoogle Scholar
  18. 18.
    Schaefer A, Jung M, Mollenkopf HJ, Wagner I, Stephan C, Jentzmik F, et al. Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer. 2010;126:1166–76.PubMedGoogle Scholar
  19. 19.
    Gandellini P, Folini M, Longoni N, Pennati M, Binda M, Colecchia M, et al. miR-205 Exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase Cepsilon. Cancer Res. 2009;69:2287–95.PubMedCrossRefGoogle Scholar
  20. 20.
    Majid S, Saini S, Dar AA, Hirata H, Shahryari V, Tanaka Y, et al. MicroRNA-205 inhibits src-mediated oncogenic pathways in renal cancer. Cancer Res. 2011;71:2611–21.PubMedCrossRefGoogle Scholar
  21. 21.
    Zidar N, Boštjančič E, Gale N, Kojc N, Poljak M, Glavač D, et al. Down-regulation of microRNAs of the miR-200 family and miR-205, and an altered expression of classic and desmosomal cadherins in spindle cell carcinoma of the head and neck—hallmark of epithelial–mesenchymal transition. Hum Pathol. 2011;42:482–8.PubMedCrossRefGoogle Scholar
  22. 22.
    Matsushima K, Isomoto H, Yamaguchi N, Inoue N, Machida H, Nakayama T, et al. MiRNA-205 modulates cellular invasion and migration via regulating zinc finger E-box binding homeobox 2 expression in esophageal squamous cell carcinoma cells. J Transl Med. 2011;9:30.PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Cao P, Zhou L, Zhang J, Zheng F, Wang H, Ma D, et al. Comprehensive expression profiling of microRNAs in laryngeal squamous cell carcinoma. Head Neck. 2013;35:720–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P, et al. MicroRNA signatures in human ovarian cancer. Cancer Res. 2007;67:8699–707.PubMedCrossRefGoogle Scholar
  25. 25.
    Sempere LF, Christensen M, Silahtaroglu A, Bak M, Heath CV, Schwartz G, et al. Altered MicroRNA expression confined to specific epithelial cell subpopulations in breast cancer. Cancer Res. 2007;67:11612–20.PubMedCrossRefGoogle Scholar
  26. 26.
    Marsit CJ, Eddy K, Kelsey KT. MicroRNA responses to cellular stress. Cancer Res. 2006;66:10843–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Kulshreshtha R, Ferracin M, Wojcik SE, Garzon R, Alder H, Agosto-Perez FJ, et al. A microRNA signature of hypoxia. Mol Cell Biol. 2007;27:1859–67.PubMedCentralPubMedCrossRefGoogle Scholar
  28. 28.
    Bergmann C, Strauss L, Wieckowski E, Czystowska M, Albers A, Wang Y, et al. Tumor-derived microvesicles in sera of patients with head and neck cancer and their role in tumor progression. Head Neck. 2009;31:371–80.PubMedCentralPubMedCrossRefGoogle Scholar
  29. 29.
    Martins VR, Dias MS, Hainaut P. Tumor-cell-derived microvesicles as carriers of molecular information in cancer. Curr Opin Oncol. 2013;25:66–75.PubMedCrossRefGoogle Scholar
  30. 30.
    Goto Y, Yue L, Yokoi A, Nishimura R, Uehara T, Koizumi S, et al. A novel single-nucleotide polymorphism in the 3′-untranslated region of the human dihydrofolate reductase gene with enhanced expression. Clin Cancer Res. 2001;7:1952–6.PubMedGoogle Scholar
  31. 31.
    Mishra PJ, Mishra P, Banerjee D, Bertino J. Dihydrofolate reductase as an oncogene. Proc Am Assoc Cancer Res. 2008;2008:2458.Google Scholar
  32. 32.
    Moldovan GL, Pfander B, Jentsch S. PCNA, the maestro of the replication fork. Cell. 2007;129:665–79.PubMedCrossRefGoogle Scholar
  33. 33.
    Maga G, Hubscher U. Proliferating cell nuclear antigen (PCNA): a dancer with many partners. J Cell Sci. 2003;116:3051–60.PubMedCrossRefGoogle Scholar
  34. 34.
    Bravo R, Frank R, Blundell PA, Macdonald-Bravo H. Cyclin/PCNA is the auxiliary protein of DNA polymerase-delta. Nature. 1987;326:515–7.PubMedCrossRefGoogle Scholar
  35. 35.
    Celis JE, Madsen P, Celis A, Hielsen HV, Gesser B. Cyclin (PCNA, auxiliary protein of DNA polymerase delta) is a central component of the pathway(s) leading to DNA replication and cell division. FEBS Lett. 1987;220:1–7.PubMedCrossRefGoogle Scholar
  36. 36.
    Sithanandam S, Anderson LM. The ERBB3 receptor in cancer and cancer gene therapy. Cancer Gene Ther. 2008;15:413–48.PubMedCentralPubMedCrossRefGoogle Scholar
  37. 37.
    Lee JS, Choi YD, Lee JH, Nam JH, Choi C, Lee MC, et al. Expression of PTEN in the progression of cervical neoplasia and its relation to tumor behavior and angiogenesis in invasive squamous cell carcinoma. J Surg Oncol. 2006;93:233–40.PubMedCrossRefGoogle Scholar
  38. 38.
    Lee JY, Park MK, Park JH, Lee HJ, Shin DH, Kang Y, et al. Loss of the polycomb protein Mel-18 enhances the epithelial-mesenchymal transition by ZEB1 and ZEB2 expression through the downregulation of miR-205 in breast cancer. Oncogene 2013. doi: 10.1038/onc.2013.53.
  39. 39.
    Slack FJ, Weidhaas JB. MicroRNA in cancer prognosis. N Engl J Med. 2008;359:2720–2.PubMedCrossRefGoogle Scholar
  40. 40.
    Li J, Chen Y, Zhao J, Kong F, Zhang Y. miR-203 reverses chemoresistance in p53-mutated colon cancer cells through downregulation of Akt2 expression. Cancer Lett. 2011;304:52–9.PubMedCrossRefGoogle Scholar
  41. 41.
    Qiu T, Zhou L, Wang T, Xu J, Wang J, Chen W, et al. miR-503 regulates the resistance of non-small cell lung cancer cells to cisplatin by targeting Bcl-2. Int Mol Med. 2013;32:593–8.Google Scholar
  42. 42.
    Wang S, Huang J, Lyu H, Lee CK, Tan J, Wang J, et al. Functional cooperation of miR-125a, miR-125b, and miR-205 in entinostat-induced downregulation of erbB2/erbB3 and apoptosis in breast cancer cells. Cell Death Dis. 2013;4:e556.PubMedCentralPubMedCrossRefGoogle Scholar
  43. 43.
    Steck Kim D, McDonnell Timothy J, El-Naggar Adel K. Flow cytometric analysis of apoptosis and BCL-2 in human solid neoplasms. Cytometry. 1995;20:154–61.PubMedCrossRefGoogle Scholar
  44. 44.
    Condon LT, Ashman JN, Ell SR, Stafford ND, Greenman J, Cawkwell L. Overexpression of Bcl-2 in squamous cell carcinoma of the larynx: a marker of radioresistance. Int J Cancer. 2002;100:472–5.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Linli Tian
    • 1
  • Jiarui Zhang
    • 1
  • Jingchun Ge
    • 1
  • Hui Xiao
    • 1
  • Jianguang Lu
    • 1
  • Songbin Fu
    • 2
  • Ming Liu
    • 1
    Email author
  • Yanan Sun
    • 1
    Email author
  1. 1.Department of Otolaryngology, Head and Neck Surgery, The Second Affiliated HospitalHarbin Medical UniversityHarbinChina
  2. 2.Laboratory of Medical GeneticsHarbin Medical UniversityHarbinChina

Personalised recommendations